Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023

Code : CMI4332

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market: Key Developments

In October 2020, Swedish Orphan Biovitrum AB, a focused worldwide biopharmaceutical business, revealed topline findings from its phase 3 research of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). Despite the fact that avatrombopag boosted platelet counts in comparison to placebo, the research did not reach the composite main goal of avoiding platelet transfusions, chemotherapy dosage reductions of 15% or more, and chemotherapy dose delays of four days or more.
In March 2022, Amgen, a worldwide biopharmaceutical company, announced the opening of its newest biomanufacturing plant in Holly Springs, North Carolina, U.S. The facility, which is set to open in 2025, will help meet the rising demand for Amgen's drugs, which treats major ailments such as cancer and heart disease. Amgen's facility will use innovative technologies to maximize productivity and assure the capacity to generate a diverse range of medications for patients.
In October 2020, the Swedish Orphan Biovitrum AB, a focused worldwide biopharmaceutical company, announced that avatrombopag (Doptelet) drug fell short in chemotherapy induced thrombocytopenia in clinical trials in phase 3. The drug did not reach the end point as per the expectations.